Microbot Medical (MBOT)
(Delayed Data from NSDQ)
$1.00 USD
+0.01 (1.01%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $1.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MBOT 1.00 +0.01(1.01%)
Will MBOT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MBOT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MBOT
Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics
Microbot Medical (MBOT) Progresses in Its Human Clinical Trial
MBOT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial
Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
Other News for MBOT
MBOT Stock Earnings: Microbot Medical Meets EPS for Q2 2024
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
Microbot Medical Nears Global Compliance, Eyes Future Goals
Microbot receives certification to support future regulatory submissions
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY? Endovascular Robotic Surgical System